UK markets close in 6 hours 26 minutes
  • FTSE 100

    6,973.20
    +33.62 (+0.48%)
     
  • FTSE 250

    22,449.87
    +94.42 (+0.42%)
     
  • AIM

    1,246.57
    +2.66 (+0.21%)
     
  • GBP/EUR

    1.1502
    +0.0005 (+0.04%)
     
  • GBP/USD

    1.3784
    +0.0003 (+0.02%)
     
  • BTC-GBP

    45,617.14
    -1,434.82 (-3.05%)
     
  • CMC Crypto 200

    1,372.69
    -3.08 (-0.22%)
     
  • S&P 500

    4,124.66
    -16.93 (-0.41%)
     
  • DOW

    33,730.89
    +53.62 (+0.16%)
     
  • CRUDE OIL

    62.93
    -0.22 (-0.35%)
     
  • GOLD FUTURES

    1,747.20
    +10.90 (+0.63%)
     
  • NIKKEI 225

    29,642.69
    +21.70 (+0.07%)
     
  • HANG SENG

    28,793.14
    -107.69 (-0.37%)
     
  • DAX

    15,261.81
    +52.66 (+0.35%)
     
  • CAC 40

    6,226.12
    +17.54 (+0.28%)
     

Peptide Therapeutics Market to Reach $47 Billion by 2027

ReportLinker
·27-min read

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 5. - Influencer Pool: 9382. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 31, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Peptide Therapeutics Industry" - https://www.reportlinker.com/p06042825/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Peptide Therapeutics Market to Reach $47 Billion by 2027
- Amid the COVID-19 crisis, the global market for Peptide Therapeutics estimated at US$27.2 Billion in the year 2020, is projected to reach a revised size of US$47 Billion by 2027, growing at aCAGR of 8.1% over the period 2020-2027. Innovative, one of the segments analyzed in the report, is projected to record 6.6% CAGR and reach US$28 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 10.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $7.4 Billion, While China is Forecast to Grow at 12.3% CAGR
- The Peptide Therapeutics market in the U.S. is estimated at US$7.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2027 trailing a CAGR of 12.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

- Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.

  • Advanced Accelerator Applications SA

  • Akashi Therapeutics, Inc.

  • Amgen, Inc.

  • Anthera Pharmaceuticals, Inc.

  • AstraZeneca PLC

  • Bachem AG

  • Bristol-Myers Squibb Company

  • Cardiorentis AG

  • Corden Pharma International GmbH

  • Debiopharm Group

  • Derma Sciences, Inc.

  • Eli Lilly and Company

  • F. Hoffmann-La Roche AG

  • GlaxoSmithKline PLC

  • Hanmi Pharmaceutical Co., Ltd.

  • Insmed, Inc.

  • Ipsen Group

  • Johnson & Johnson

  • Lonza Group AG

  • Mallinckrodt PLC

  • Merck & Co., Inc.

  • MolMed S.p.A.

  • Novartis AG

  • Novo Nordisk A/S

  • Nymox Pharmaceutical Corporation

  • PAR Pharmaceutical Companies, Inc.

  • PeptiDream Inc.

  • Pfizer, Inc.

  • PolyPeptide Group

  • Radius Health, Inc.

  • Repligen Corporation

  • Sanofi SA

  • SciClone Pharmaceuticals Holding Limited.

  • Shire PLC

  • Takeda Pharmaceutical Co., Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • The Medicines Company

  • X-GEN Pharmaceuticals, Inc.

  • Zealand Pharma A/S

  • Zydus Cadila




Read the full report: https://www.reportlinker.com/p06042825/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Peptide
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Peptide Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Peptide Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Innovative by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Innovative by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Innovative by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Generic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Generic by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Generic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Liquid Phase by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Liquid Phase by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Liquid Phase by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Solid Phase by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Solid Phase by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Solid Phase by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Hybrid Phase by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Hybrid Phase by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Hybrid Phase by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Cancer by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Cancer by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Cardiovascular
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Cardiovascular Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Cardiovascular Disease
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Metabolic Disease
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Metabolic Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Metabolic Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Respiratory
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Respiratory Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Respiratory Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Infectious
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Infectious Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Infectious Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 37: USA Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 38: USA Historic Review for Peptide Therapeutics by Type -
Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 39: USA 15-Year Perspective for Peptide Therapeutics by
Type - Percentage Breakdown of Value Sales for Innovative and
Generic for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Peptide Therapeutics by
Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 43: USA Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Peptide Therapeutics by
Application - Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Disease, Metabolic Disease, Respiratory Disease,
Infectious Disease and Other Applications for the Years 2012,
2020 & 2027

CANADA
Table 46: Canada Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 47: Canada Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 48: Canada 15-Year Perspective for Peptide Therapeutics
by Type - Percentage Breakdown of Value Sales for Innovative
and Generic for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Peptide Therapeutics
by Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 52: Canada Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Peptide Therapeutics
by Application - Percentage Breakdown of Value Sales for
Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory
Disease, Infectious Disease and Other Applications for the
Years 2012, 2020 & 2027

JAPAN
Table 55: Japan Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 56: Japan Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 57: Japan 15-Year Perspective for Peptide Therapeutics by
Type - Percentage Breakdown of Value Sales for Innovative and
Generic for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Peptide Therapeutics by
Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 61: Japan Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Peptide Therapeutics by
Application - Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Disease, Metabolic Disease, Respiratory Disease,
Infectious Disease and Other Applications for the Years 2012,
2020 & 2027

CHINA
Table 64: China Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 65: China Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 66: China 15-Year Perspective for Peptide Therapeutics by
Type - Percentage Breakdown of Value Sales for Innovative and
Generic for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Peptide Therapeutics by
Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 70: China Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Peptide Therapeutics by
Application - Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Disease, Metabolic Disease, Respiratory Disease,
Infectious Disease and Other Applications for the Years 2012,
2020 & 2027

EUROPE
Table 73: Europe Current & Future Analysis for Peptide
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 74: Europe Historic Review for Peptide Therapeutics by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Peptide Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 77: Europe Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 78: Europe 15-Year Perspective for Peptide Therapeutics
by Type - Percentage Breakdown of Value Sales for Innovative
and Generic for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Peptide Therapeutics
by Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 82: Europe Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Peptide Therapeutics
by Application - Percentage Breakdown of Value Sales for
Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory
Disease, Infectious Disease and Other Applications for the
Years 2012, 2020 & 2027

FRANCE
Table 85: France Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 86: France Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 87: France 15-Year Perspective for Peptide Therapeutics
by Type - Percentage Breakdown of Value Sales for Innovative
and Generic for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Peptide Therapeutics
by Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 91: France Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: France Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 93: France 15-Year Perspective for Peptide Therapeutics
by Application - Percentage Breakdown of Value Sales for
Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory
Disease, Infectious Disease and Other Applications for the
Years 2012, 2020 & 2027

GERMANY
Table 94: Germany Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 95: Germany Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 96: Germany 15-Year Perspective for Peptide Therapeutics
by Type - Percentage Breakdown of Value Sales for Innovative
and Generic for the Years 2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 98: Germany Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Peptide Therapeutics
by Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 100: Germany Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 101: Germany Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Germany 15-Year Perspective for Peptide Therapeutics
by Application - Percentage Breakdown of Value Sales for
Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory
Disease, Infectious Disease and Other Applications for the
Years 2012, 2020 & 2027

ITALY
Table 103: Italy Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 104: Italy Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 105: Italy 15-Year Perspective for Peptide Therapeutics
by Type - Percentage Breakdown of Value Sales for Innovative
and Generic for the Years 2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 107: Italy Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Peptide Therapeutics
by Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 109: Italy Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 110: Italy Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 111: Italy 15-Year Perspective for Peptide Therapeutics
by Application - Percentage Breakdown of Value Sales for
Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory
Disease, Infectious Disease and Other Applications for the
Years 2012, 2020 & 2027

UNITED KINGDOM
Table 112: UK Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 113: UK Historic Review for Peptide Therapeutics by Type -
Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 114: UK 15-Year Perspective for Peptide Therapeutics by
Type - Percentage Breakdown of Value Sales for Innovative and
Generic for the Years 2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 116: UK Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Peptide Therapeutics by
Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 118: UK Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 119: UK Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 120: UK 15-Year Perspective for Peptide Therapeutics by
Application - Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Disease, Metabolic Disease, Respiratory Disease,
Infectious Disease and Other Applications for the Years 2012,
2020 & 2027

SPAIN
Table 121: Spain Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 122: Spain Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 123: Spain 15-Year Perspective for Peptide Therapeutics
by Type - Percentage Breakdown of Value Sales for Innovative
and Generic for the Years 2012, 2020 & 2027

Table 124: Spain Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 125: Spain Historic Review for Peptide Therapeutics by
Technology - Liquid Phase, Solid Phase and Hybrid Phase Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 126: Spain 15-Year Perspective for Peptide Therapeutics
by Technology - Percentage Breakdown of Value Sales for Liquid
Phase, Solid Phase and Hybrid Phase for the Years 2012, 2020 &
2027

Table 127: Spain Current & Future Analysis for Peptide
Therapeutics by Application - Cancer, Cardiovascular Disease,
Metabolic Disease, Respiratory Disease, Infectious Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 128: Spain Historic Review for Peptide Therapeutics by
Application - Cancer, Cardiovascular Disease, Metabolic
Disease, Respiratory Disease, Infectious Disease and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 129: Spain 15-Year Perspective for Peptide Therapeutics
by Application - Percentage Breakdown of Value Sales for
Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory
Disease, Infectious Disease and Other Applications for the
Years 2012, 2020 & 2027

RUSSIA
Table 130: Russia Current & Future Analysis for Peptide
Therapeutics by Type - Innovative and Generic - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 131: Russia Historic Review for Peptide Therapeutics by
Type - Innovative and Generic Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 132: Russia 15-Year Perspective for Peptide Therapeutics
by Type - Percentage Breakdown of Value Sales for Innovative
and Generic for the Years 2012, 2020 & 2027

Table 133: Russia Current & Future Analysis for Peptide
Therapeutics by Technology - Liquid Phase, Solid Phase and
Hybrid Phase - Independent Analysis of Annual Sales in US$

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06042825/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001